Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: A move towards a unified glucose tetrad concept

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 5, 2009, Pages 393-402

  Monnier, Louis ^a   Colette, Claude ^a   Owens, David R ^b  

^a LAPEYRONIE HOSPITAL   (France)

^b LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Continuous glucose monitoring system; Glycaemic variability; Postprandial glucose; Type 2 diabetes

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACARBOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; PLACEBO; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; GLYCEMIC INDEX; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SELF MONITORING; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; DIABETIC ANGIOPATHY; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; METABOLISM; MONITORING; PHYSIOLOGY; STANDARD;

ATHEROSCLEROSIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; MONITORING, PHYSIOLOGIC; POSTPRANDIAL PERIOD;

EID: 70350639460     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.962     Document Type: Review

References (90)

1. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23: B21-B29. (Pubitemid 30185774)
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412. (Pubitemid 30609442)
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
4. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653. (Pubitemid 41817713)
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
7. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622. (Pubitemid 29087981)
8. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl JMed 2003; 348: 383-393. (Pubitemid 36159355)
9. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008; 31(Suppl. 1): S4-41.
10. Lebovitz HE, Austin MM, Blonde L, et al. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006; 12: 6-12. (Pubitemid 44963603)
11. International Diabetes Federation. Guideline for Management of Postmeal Glucose. IDF: Brussels, 2007; 1-27.
12. National Center for Health Statistics: NHANES 1999-2000. Hyattsville, MD, US. Department of Health and Human Service, Centers for Disease Control and Prevention, National Center for Health Statistics, Available from www.cdc.gov/nchs/about/major/nhanes/nhanes99 00.htm.
13. National Center for Health Statistics: NHANES 2001-2002. Hyattsville, MD, U.S. Department of Health and Human Service, Centers for Disease Control and Prevention, National Center for Health Statistics, Available from www.cdc.gov/nchs/about/major/nhanes/nhanes01 02.htm.
14. National Center for Health Statistics: NHANES 2003-2004. Hyattsville, MD, US. Department of Health and Human Service, Centers for Disease Control and Prevention, National Center for Health Statistics, Available from www.cdc.gov/nchs/about/major/nhanes/nhanes03 04.htm.
15. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
16. The ADVANCE Collaborative Group. Intensive blood control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
17. Duckworth W, Abraira C, Moritz T, et al, for the VADT Investigators. Glucose control and vascular complications in Veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
18. El-Kebbi IM, Ziemer DC, Cook CB, Gallina DL, Barnes CS, Phillips LS. Utility of casual postprandial glucose levels in type 2 diabetes management. Diabetes Care 2004; 27: 335-339. (Pubitemid 38174054)
19. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972. (Pubitemid 44156663)
20. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J, The Chicago Heart Association Detection Project in Industry Study. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. Diabetes Care 1997; 20: 163-169. (Pubitemid 27051554)
21. The DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
22. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004; 47: 385-394. (Pubitemid 38491233)
23. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002; 25: 1845-1850. (Pubitemid 41071098)
24. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A, The Funagata Diabetes Study. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 1999; 22: 920-924. (Pubitemid 29241045)
25. Donahue RP, Abbott RD, Reed DM, Yano K, Honolulu Heart Program. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Diabetes 1987; 36: 689-692.
26. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926-931. (Pubitemid 29369599)
27. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001; 24: 1397-1402. (Pubitemid 33716427)
28. Barrett-Connor E, Ferrara A, The Rancho Bernardo Study. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. Diabetes Care 1998; 21: 1236-1239. (Pubitemid 28365676)
29. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367. (Pubitemid 28101069)
30. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240. (Pubitemid 29056916)
31. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006; 91: 813-819. (Pubitemid 43357744)
32. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30: 263-269. (Pubitemid 46198328)
33. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 1231-1239. (Pubitemid 18120885)
34. Service FJ, O'Brien PC, Rizza RA. Measurements of glucose control. Diabetes Care 1987; 10: 225-237.
35. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19: 644-655.
36. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in noninsulin- dependent diabetes mellitus. N Engl J Med 1992; 327: 707-713.
37. Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest 2000; 30: 3-11. (Pubitemid 30604060)
38. Monnier L, Colette C, Thuan JF, Lapinski H. Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. Eur J Clin Invest 2006; 36: 231-235.
39. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001; 44: 929-945. (Pubitemid 32778125)
40. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10- year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290-296. (Pubitemid 28168508)
41. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
42. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19. (Pubitemid 36237741)
43. Yki-Järvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 1995; 38: 1378-1388.
44. Radziuk J, Pye S. Quantitation of basal endogenous glucose production in Type II diabetes: importance of the volume of distribution. Diabetologia 2002; 45: 1053-1084. (Pubitemid 34985283)
45. Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 1996; 45: 1044-1050. (Pubitemid 26260156)
46. Bolli GB, Gerich JE. The "dawn phenomenon" - a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 1984; 310: 746-750.
47. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794. (Pubitemid 29536364)
48. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio Metabolism (SAM) study. Diabetologia 2004; 37: 31-39. (Pubitemid 38141937)
49. Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 2003; 46(Suppl. 1): M2-M8. (Pubitemid 36543097)
50. Bonadonna RC, Stumvoll M, Fritsche A, et al. Altered homeostatic adaptation of first-and second-phase β-cell secretion in the offspring of patients with type 2 diabetes. Diabetes 2003; 52: 470-480.
51. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, De Fronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance. Diabetes 2006; 55: 1430-1435.
52. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-278. (Pubitemid 41079621)
53. Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001; 24: 2023-2029. (Pubitemid 33716515)
54. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20: 1822-1826. (Pubitemid 27522889)
55. Ceriello A. Postprandial hyperglycemia and diabetes complications. Is it time to treat? Diabetes 2005; 54: 1-7. (Pubitemid 40105088)
56. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687.
57. Hasegawa G, Yamamoto Y, Zhi JG, et al. Daily profile of plasma %CoQ10 level, a biomarker of oxidative stress, in patients with diabetes manifesting postprandial hyperglycaemia. Acta Diabetol 2005; 42: 179-181. (Pubitemid 43029837)
58. Davi G, Falco A, Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal 2005; 7: 256-268.
59. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004; 53: 701-710. (Pubitemid 38270640)
60. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003; 26: 1589-1596.
61. Ceriello A, Quagliaro L, Catone B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002; 25: 1439-1443. (Pubitemid 41071158)
62. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820. (Pubitemid 34000785)
63. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625. (Pubitemid 40770750)
64. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003; 46: M9-16. (Pubitemid 36543098)
65. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 1349-1354.
66. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29: 1486-1490. (Pubitemid 44127568)
67. Lachin JM, Genuth S, Nathan DM, Zinman B,Rutledge BN for the DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-Revisited. Diabetes 2008; 57: 995-1001.
68. Raz I, Wilson PWF, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the Heart2D trial. Diabetes Care 2009; 32: 381-386.
69. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885. (Pubitemid 36929359)
70. American Diabetes Association. The Expert Committee in the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes mellitus. Diabetes Care 2002; 25(Suppl. 1): S5-S20.
71. American Diabetes Association. Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 2002; 25(Suppl. 1): S33-S49.
72. Monnier L, Colette C, Rabasa-Lhoret R, et al. Morning hyperglycemic excursions : a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002; 25: 737-741. (Pubitemid 41071196)
73. Pearce KL, NoakesM, Keogh J, Clifton PM. Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes. Am J Clin Nutr 2008; 87: 638-644.
74. Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 846-854.
75. Monnier L, Colette C, Boniface H. Contribution of postprandial glucose to chronic hyperglycemia: from the "glucose triad" to the trilogy of "sevens". Diabetes Metab 2006; 32: 2S11-2S16.
76. Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 2006; 32: 7-13. (Pubitemid 43872590)
77. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583. (Pubitemid 26397370)
78. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494. (Pubitemid 37430502)
79. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16. (Pubitemid 38055587)
80. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-219. (Pubitemid 38924590)
81. Monnier L, Colette C, Leiter L, et al. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2007; 30: 185-186.
82. Mastrototaro J. The MiniMed continuous glucose monitoring system (CGMS). J Pediatr Endocrinol Metab 1999; 12: 751-758. (Pubitemid 30002854)
83. Rebrin K, Steil GM. Can Intestinal glucose assessment replace blood glucose measurements? Diabetes Technol Ther 2000; 2: 461-472. (Pubitemid 30836005)
84. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464-1476.
85. Ajjan RA, Grant PJ. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents. Diabetes Vasc Dis Res 2006; 3: 147-158. (Pubitemid 44902480)
86. Hinnen D, Nielsen LL, Waninger A, Kushner P. Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes. J Am Board FamMed 2006; 19: 612-620. (Pubitemid 44739909)
87. Koski RR. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus. Diabetes Educ 2006; 32: 869-876. (Pubitemid 44706815)
88. Riddle M, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care 2003; 26: 3080-3086.
89. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care 2008; 31: S150-S154.
90. Lankisch M, Ferlinz K, Scherbaum WA. Basal insulin and oral diabetics therapy (BOT) plus a single dose of insulin glulisine (BOT+) reduces HbA1c and blood glucose values in patients with type 2 diabetes (abstract 198-OR). Diabetes 2007; 56: A51.